What is B. Riley's Estimate for CNTA Q1 Earnings?

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Analysts at B. Riley lowered their Q1 2025 earnings per share estimates for Centessa Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.38) for the quarter, down from their previous estimate of ($0.36). The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. B. Riley also issued estimates for Centessa Pharmaceuticals' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($2.01) EPS and FY2027 earnings at ($2.33) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04.

Several other brokerages also recently weighed in on CNTA. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating on the stock. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday. They set an "overweight" rating and a $38.00 target price for the company. Finally, Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Buy" and an average price target of $27.71.

Remove Ads

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA traded up $0.60 during trading on Monday, reaching $13.83. The company had a trading volume of 456,083 shares, compared to its average volume of 553,669. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.04 and a beta of 1.54. The stock's fifty day moving average price is $16.40 and its 200 day moving average price is $16.41. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals during the fourth quarter worth $31,000. GAMMA Investing LLC lifted its position in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC boosted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after buying an additional 4,952 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $171,000. Institutional investors own 82.01% of the company's stock.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $16.34, for a total transaction of $163,400.00. Following the completion of the sale, the insider now directly owns 134,021 shares of the company's stock, valued at approximately $2,189,903.14. This represents a 6.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total value of $917,950.00. Following the transaction, the chief executive officer now directly owns 276,017 shares in the company, valued at $4,606,723.73. This trade represents a 16.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 260,168 shares of company stock worth $4,309,568. 11.59% of the stock is owned by company insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.